Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.

Autor: Howe MD; Dr. Matthew Howe, Butler Hospital Memory and Aging Program, 345 Blackstone Boulevard, Providence, RI 02906, USA, Phone: 401-455-6403, Fax: 401-455-6405, Email: matthew_howe@brown.edu., Britton KJ, Joyce HE, Pappas GJ, Faust MA, Dawson BC, Riddle MC, Salloway SP
Jazyk: angličtina
Zdroj: The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2023; Vol. 10 (4), pp. 765-770.
DOI: 10.14283/jpad.2023.96
Abstrakt: Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer's disease. There is little real-world data to guide management of amyloid-related imaging abnormalities (ARIA), a potentially serious side-effect which requires surveillance with magnetic resonance imaging. We report our experiences in managing ARIA in patients receiving aducanumab at the Butler Hospital Memory and Aging Program during the year following FDA approval. We followed the Appropriate Use Recommendations for aducanumab to guide patient selection, detection, and management of ARIA (1). ARIA-E occurred in 6 out of 24 participants treated; all APOE-ε4 carriers. Treatment was discontinued in 4 cases of moderate-severe ARIA-E, temporarily held in 1 moderate case, and dosed through in 1 mild case (mean duration = 3 months, range, 1-6 months). No participants required hospitalization or high dose corticosteroids. Participants on anticoagulation were excluded and no macrohemorrhages occurred. These data support the measured approaches to treatment outlined in the Appropriate Use Recommendations.
Competing Interests: M. Howe: None to disclose. K. Britton: None to disclose. H. Joyce: None to disclose. G. Pappas: None to disclose. M. Faust: None to disclose. B. Dawson: None to disclose. M. Riddle: None to disclose. S. Salloway: Dr. Salloway has provided consultation to Biogen, Eisai, Avid, Lilly, Genentech, and Roche; he was a site principal investigator on the PRIME and ENGAGE studies and co-chair of the Investigator Steering Committee for the ENGAGE study. Dr. Salloway is an author on the AUR for Aducanumab (1) and Lecanemab (15) and is the first author on the report of ARIA in the aducanumab phase 3 program (5). Butler Hospital has received research grants from Biogen, Eisai, Avid, Roche, Genentech, Janssen and Lilly.
Databáze: MEDLINE
Externí odkaz: